Group 1 - The core point of the news is that Buchang Pharmaceutical is expanding its business by investing in new companies through its subsidiaries, reflecting confidence in its growth prospects due to strong financial performance in the first half of 2025 [1][3][4] Group 2 - Buchang Pharmaceutical's subsidiary, Shanghai Hupu Medical Technology Co., Ltd., plans to invest a total of 4.9 million yuan to establish two new companies in partnership with Jinan Hengde Technology Development Co., Ltd. and Shanghai Guoding Technology Co., Ltd. [1] - The registered capital for Shandong Hupu Ruicheng Medical Technology Co., Ltd. is 4 million yuan, with Shanghai Hupu contributing 2.8 million yuan for a 70% stake, while Jinan Hengde contributes 1.2 million yuan for a 30% stake [3] - The registered capital for Hubei Hupu Medical Technology Co., Ltd. is 3 million yuan, with Shanghai Hupu contributing 2.1 million yuan for a 70% stake, and Shanghai Guoding contributing 900,000 yuan for a 30% stake [3] - Previously, another subsidiary, Shandong Buchang Chuanfang Pharmaceutical Co., Ltd., partnered with Zero Medical Technology (Shaanxi) Co., Ltd. to establish Shaanxi Buchang Medical Technology Co., Ltd. with a registered capital of 5 million yuan [3] Group 3 - In the first half of 2025, Buchang Pharmaceutical achieved revenue of 5.664 billion yuan and a net profit attributable to shareholders of 628 million yuan, representing year-on-year growth of 4.27% and 171.24%, respectively [4] - For the first and second quarters of 2025, the company reported revenues of 2.785 billion yuan and 2.879 billion yuan, with year-on-year growth of 5.47% and 3.14%, and net profits of 307 million yuan and 320 million yuan, reflecting year-on-year growth of 169.49% and 172.94% [4] - The significant increase in net profit is attributed to higher sales volume, lower production costs, and the reduction of amortization related to acquisitions made in previous years [4]

Core Viewpoint - The stock of Buchang Pharmaceutical (603858.SH) is currently in a state of decline, with a closing price of 18.67 yuan and a drop of 3.21% [1] Group 1: Company Overview - Buchang Pharmaceutical was listed on the Shanghai Stock Exchange on November 18, 2016, with an issuance of 69.8 million shares at an initial price of 55.88 yuan [1] - The total amount raised from this issuance was 390,042.40 thousand yuan, with a net amount of 367,143.57 thousand yuan after deducting issuance costs [1] Group 2: Fund Utilization - The funds raised are intended for the construction of a cardiovascular drug production base in Shaanxi, as well as for supplementing working capital and repaying bank loans [1] - The total issuance costs for this public offering amounted to 22,898.83 thousand yuan, with the underwriter and sponsor, CITIC Securities, receiving 21,974.80 thousand yuan in fees [1]

Policy Developments - The 2025 Pharmaceutical Digital Development Conference was held in Beijing on September 17-18, focusing on the modernization of drug regulation through information technology and digital collaboration [1] Drug and Device Approvals - Hengrui Medicine's SHR-1501 has been included in the list of proposed breakthrough therapy varieties by the National Medical Products Administration, aimed at treating non-muscle invasive bladder cancer [2] - Kehua Bio's ferritin assay kit received a medical device registration certificate, valid from September 17, 2025, to September 16, 2030, for the quantitative measurement of ferritin in human serum and plasma [3] - Shanghai Pharmaceuticals' Nicorandil tablets passed the consistency evaluation for generic drugs, with approximately 5.5352 million yuan invested in R&D [4] Capital Market - Roche announced a definitive agreement to acquire biopharmaceutical company 89bio for up to nearly $3.5 billion, focusing on innovative therapies for liver and heart metabolic diseases [5] Industry Events - The first national group standard for "Non-Clinical Safety Technical Guidelines for Oligonucleotide Drugs" was released during the 9th China (Tianjin) Nucleic Acid Drug Conference [6] Research and Development - Chinese researchers developed a new generation of brain-machine interface electrodes, marking a shift towards dynamic and intelligent detection in bioelectronic interfaces [7] - A new blood testing tool, "HPV-DeepSeek," can identify HPV-related head and neck cancers up to 10 years before symptoms appear, potentially improving patient outcomes [9] Corporate Governance - The independent director of Buchang Pharma, Cheng Hua, resigned due to personal reasons, leading to a temporary reduction in the number of independent directors on the board [10] Strategic Collaborations - Siemens Healthineers and Stryker announced a strategic partnership to develop a new robotic system for neurovascular interventions [8]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603858 证券简称：步长制药 公告编号：2025-183 山东步长制药股份有限公司 关于召开2025年半年度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025年09月26日（星期五）上午11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动问答 投资者可于2025年09月19日 （星期五） 至09月25日 （星期四）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱（ir@buchang.com）进行提问。公司将在信息披露允许的范围内于 说明会上对投资者普遍关注的问题进行回答。 山东步长制药股份有限公司（以下简称"公司"）已于2025年8月28日发布公司《2025年半年度报告》， 为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年 ...

证券日报网讯 9月18日晚间，步长制药发布公告称，公司董事会于近日收到独立董事程华女士的书面辞 呈，由于个人原因，程华女士辞去公司第五届董事会独立董事、董事会审计委员会主任委员、董事会提 名委员会委员、董事会薪酬与考核委员会主任委员职务，辞职后不再担任公司任何职务。 （编辑 楚丽君） ...

9月17日，步长制药发布2025年半年度权益分派实施公告，每股派发现金红利0.39元，共计派发4.11亿 元，将于9月25日至9月26日内发放。步长制药此次分红实施方案已经公司第五届董事会第三十次会议审 议通过，以方案实施前的公司总股本10.55亿股为基数进行派发。这样的分红力度，展现出公司对股东 回报的重视及稳健的现金流。 分红趋势明显，高股息率加大回报股东力度 近年来，随着监管层鼓励上市公司加大现金分红力度，越来越多的医药企业选择在中期进行分红。步长 制药积极响应落实新"国九条"，上市以来首次开展中期分红，把股东回报从"纸面上"落实到"行动中"。 从已披露的2025年中期分红方案来看，医药行业各细分领域的龙头企业都展现出了较强的分红意愿。截 至目前，已有包括药明康德、东阿阿胶、华润三九、白云山药业等公司发布分红计划，且都以每10股超 4元的派现作为分红方案，显示出医药行业对于投资者回报的重视。 步长制药每股派息0.39元，处于行业中上水平。从股息率角度来看，步长制药股息率2.52%，高于分红 数额靠前的药明康德、东阿阿胶等企业。股息率是衡量上市公司投资价值的重要指标之一，较高的股息 率往往意味着较好的投资 ...

中证报中证网讯（王珞）9月17日—19日，第十二届中国—东盟（泰国）商品贸易展览会在泰国曼谷举 行，步长制药应邀参展。 此次参展，步长制药不仅向东南亚市场集中展现了自身的产品优势与发展成果，更为深化国际交流合作 搭建了重要桥梁。未来，步长制药将持续推进国际化布局，把更多高品质的产品带给全球消费者。 展会伊始，步长制药展位便吸引了众多嘉宾与采购商的关注，不少人表示熟悉并服用过脑心通等产品。 值得一提的是，泰国中华总商会会长李桂雄一行在巡展期间，在步长制药展位前长时间驻足，与步长制 药相关负责人展开深入交流。 截至目前，步长制药已有9个产品获得泰国卫生部注册批文，另有多个产品正处于审批流程中，步长制 药在泰国的产品集群正加速形成。 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-183 山东步长制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 山东步长制药股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日发 布公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 26 日 （星期五） 11:00-12:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 会议召开时间：2025 年 09 月 26 日（星期五）上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadsho w.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动问答 投资者可于 2025 年 09 月 19 日 （星期五） 至 09 月 25 日 （星期四） 16:00 前登录上证路演中心网站首页点击"提问预征集" ...

证券代码：603858 证券简称：步长制药 公告编号：2025-184 山东步长制药股份有限公司 关于公司独立董事辞职的公告 鉴于程华女士的辞职将导致公司独立董事人数低于《公司章程》规定的董事 会人数的三分之一，且程华女士作为会计专业人士，根据《上市公司独立董事管 理办法》，在新任独立董事任职资格经监管部门核准且公司股东会完成选举之前， 程华女士将按照有关法律法规和《公司章程》的规定，继续履行独立董事及其在 董事会专门委员会中的相应职责。公司将根据《公司法》、《上市公司独立董事管 理办法》以及《公司章程》等相关规定，按照法定程序尽快完成独立董事的补选 工作。 程华女士自担任公司独立董事职务以来，恪尽职守、勤勉尽责，为公司发展 发挥了积极作用。公司及董事会对程华女士在公司发展过程中做出的贡献表示衷 心感谢！ 特此公告。 山东步长制药股份有限公司公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原因 | 是否继续在上 市公司及其控 股子公司任职 | 具体 ...

Core Viewpoint - The stock of Buchang Pharma has shown a positive trend with a year-to-date increase of 21.90%, despite a slight decline in the last five trading days [1] Group 1: Stock Performance - On September 18, Buchang Pharma's stock rose by 2.01%, reaching 19.26 CNY per share, with a trading volume of 51.29 million CNY and a turnover rate of 0.25% [1] - The total market capitalization of Buchang Pharma is 20.31 billion CNY [1] - The stock has experienced a 0.31% decline over the last five trading days, a 0.47% increase over the last 20 days, and a 19.18% increase over the last 60 days [1] Group 2: Financial Performance - For the first half of 2025, Buchang Pharma reported a revenue of 5.664 billion CNY, representing a year-on-year growth of 4.27% [2] - The net profit attributable to shareholders for the same period was 628 million CNY, showing a significant year-on-year increase of 171.24% [2] - Since its A-share listing, Buchang Pharma has distributed a total of 7.948 billion CNY in dividends, with 1.609 billion CNY distributed over the past three years [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Buchang Pharma is 55,200, a decrease of 7.32% from the previous period [2] - The average number of circulating shares per shareholder is 20,054, which has increased by 7.89% compared to the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 500 ETF, with significant increases in their holdings [2]